Skip to main content
Midas Edge

RenovoRx, Inc.

For the period ended Dec 31, 2024. Filed Apr 1, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 1, 2025

RNXT$1.180.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated Other Comprehensive · Accumulated · Total Stockholders’ Equity
Shares · Amount · Shares · Amount · Capital · Income (Loss) · Deficit · (Deficit)
Balance—December 31, 2022-$-9,097,701$1$37,318$17$(31,173)$6,163
Issuance of common stock upon exercise of stock options--8,247-8--8
Issuance of restricted stock awards--30,000-----
Issuance of common stock upon the registered direct offering--1,000,000-----
Issuance and exercise of common stock warrants upon the registered direct offering--557,632-----
Stock-based compensation expense----1,078--1,078
Other comprehensive income-----(17)-(17)
Net loss------(10,232)(10,232)
Balance—December 31, 2023--10,693,580$1$38,404$-$(41,405)$(3,000)
Issuance of common stock upon the private placement offering--13,094,278115,015--15,016
Issuance of restricted stock awards--120,000-----
Issuance of common stock upon exercise of stock options--93,481-69--69
Issuance of common stock upon exercise of common stock warrants--33,333-33--33
Stock-based compensation expense----1,174--1,174
Net loss------(8,814)(8,814)
Balance—December 31, 2024-$-24,034,672$2$54,695$-$(50,219)$4,478
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.